Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LifeCycle Pharma has successfully completed the pilot studies for LCP-Feno, a product for the treatment of dyslipidemia which is being developed in collaboration with Sandoz.
Subscribe to our email newsletter
LCP-Feno is designed to be an AB-rated, substitutable version of Tricor 145mg, currently marketed in the US by Abbott under the name Tricor and in Europe by Solvay under the name Lipanthyl.
In collaboration with Sandoz, LifeCycle Pharma is currently preparing for the initiation of pivotal studies to complete all the necessary requirements for an US abbreviated new drug application filing.
Michael Beckert, chief medical officer and executive vice president of LifeCycle, said: “We are extremely pleased to have shown bioequivalence of LCP-Feno and Tricor in this pilot study. This is another important milestone for the company, and a clear validation of the breadth of application as well as versatility of the MeltDose technology. The next step will be to prepare for pivotal pharmacokinetic studies to confirm these results.”